Literature DB >> 10585206

Structure-activity relationship studies of novel heteroretinoids: induction of apoptosis in the HL-60 cell line by a novel isoxazole-containing heteroretinoid.

D Simoni1, F P Invidiata, R Rondanin, S Grimaudo, G Cannizzo, E Barbusca, F Porretto, N D'Alessandro, M Tolomeo.   

Abstract

In a search for retinoic acid receptor (RAR and RXR)-selective ligands, a series of isoxazole retinoids was synthesized and evaluated in vitro in transcriptional activation and competition binding assays for RARs and RXRs. In addition, these compounds were evaluated for their differentiating, cytotoxic, and apoptotic activities. In general, these derivatives showed scarcely any binding affinity and were not active in the transcriptional assay. However, among these isoxazole derivatives, the cis-isomer 14b was identified as a potent inducer of apoptosis, and its activity was found to be 6.5 and 4 times superior than that of 13-cis- and 9-cis-retinoic acids, respectively. On the other hand, compound 13b, which has the trans stereochemistry at the double bond, was found not to be active in the apoptotic assay, but it was endowed with appreciable differentiating activity. Therefore, it seems that the different stereochemistry of the double bond may be associated with a different biological activity: potent apoptotic activity for the cis-isomer but differentiating activity for the trans structure. This biological behavior was found, at least in part, for the 9-cis- and 13-cis-retinoic acids with respect to the all-trans-retinoic acid. Thus, structure 14b could offer an interesting model for the design of new compounds endowed with apoptotic activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10585206     DOI: 10.1021/jm991059n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines.

Authors:  M Tolomeo; S Grimaudo; S Milano; M La Rosa; V Ferlazzo; G Di Bella; C Barbera; D Simoni; P D'Agostino; E Cillari
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity.

Authors:  Irina N Gaisina; Werner Tueckmantel; Andrey Ugolkov; Sida Shen; Jessica Hoffen; Oleksii Dubrovskyi; Andrew Mazar; Renee A Schoon; Daniel Billadeau; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2015-11-23       Impact factor: 3.466

3.  Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.

Authors:  Subhasish Tapadar; Rong He; Doris N Luchini; Daniel D Billadeau; Alan P Kozikowski
Journal:  Bioorg Med Chem Lett       Date:  2009-04-20       Impact factor: 2.823

4.  In vitro activities of novel 4-HPR derivatives on a panel of rhabdoid and other tumor cell lines.

Authors:  Melissa E Smith; Bhaskar C Das; Ganjam V Kalpana
Journal:  Cancer Cell Int       Date:  2011-09-27       Impact factor: 5.722

5.  Crystal structure of 1-{3-acetyl-2-(4-chloro-phen-yl)-6-hy-droxy-4-[(2-hy-droxy-prop-yl)amino]-6-methyl-cyclo-hex-3-en-1-yl}ethanone.

Authors:  Shaaban K Mohamed; Joel T Mague; Mehmet Akkurt; Antar A Abdelhamid; Mustafa R Albayati
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-04-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.